Hovione upping spray drying capacity to support rise in low solubility drugs

By Dan Stanton

- Last updated on GMT

Hovione upping SDD capacity to support rise in low solubility drugs

Related tags Solubility

A new unit will up Hovione’s spray drying capacity 20% as it predicts a surge in demand for such a service in overcoming drug solubility issues.

An additional large-scale spray drying unit at Hovione’s facility in Loures, Portugal, is set to be operational by March next year, and is the first phase of a broad expansion of the firm’s spray-dry services designed to meet increased demand.

“This new unit will allow us to produce between 50 and 200 metric tons of spray dried products per year,”​ Filipe Gaspar, VP of R&D at Hovione, told in-Pharmatechnologist.com. “It represents an increase in 20% of Hovione’s current installed capacity.”


“Spray drying is becoming the leading platform to overcome the poor solubility of most modern oral drugs,” ​he said, adding each year one or two new oral drug products reach the market using the technology.

“[It] is a preferred process when producing highly soluble amorphous materials when isolating thermal sensitive products or when precise control over particle morphology, size and power attributes are required. Many of these advanced materials have high potency but spray drying technology can be adjusted to meet the inherent requirements.”

But among the service providers, “there is intense competition in early stage development and to a lesser extent in late stage and commercial spray drying though the latter will increase in the upcoming years.”

Just last week​, Capsugel announced it had completed a $25m expansion at its facility in Bend, Oregon, adding a third commercial-scale dryer.

“Multiple offerings, competition, helps considerably in making spray drying an established technology in Pharma and that is good news for all of us,”​ said Gaspar who added Hovione was one of the early adaptors with more than 10 years commercial spray-dry experience.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more